[1] UCCELLI A, MORETTA L, PISTOIA V. Mesenchymal Stem Cells in Health and Disease. Nat Rev Immunol. 2008;8(9):726-736.
[2] ANDRZEJEWSKA A, LUKOMSKA B, JANOWSKI M. Concise Review: mesenchymal stem cells: from roots to boost. Stem Cells. 2019;37(7):855-864.
[3] LENG Z, ZHU R, HOU W, et al. Transplantation of Ace2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with Covid-19 Pneumonia. Aging Dis. 2020;11(2):216-228.
[4] GIACCO F, BROWNLEE M. Oxidative Stress and Diabetic Complications. Circ Res. 2010;107(9):1058-1070.
[5] CHOW F, OZOLS E, NIKOLIC-PATERSON DJ, et al. Macrophages in Mouse Type 2 Diabetic Nephropathy: Correlation with Diabetic State and Progressive Renal Injury. Kidney Int. 2004;65(1):116-128.
[6] TIAN S, CHEN SY. Macrophage Polarization in Kidney Diseases. Macrophage (Houst). 2015;2(1):e679.
[7] KLESSENS CQF, ZANDBERGEN M, WOLTERBEEK R, et al. Macrophages in Diabetic Nephropathy in Patients with Type 2 Diabetes. Nephrol Dial Transplant. 2017;32(8):1322-1329.
[8] NAVARRO-GONZÁLEZ JF, MORA-FERNÁNDEZ C, MUROS DE FUENTES M, et al. Inflammatory Molecules and Pathways in the Pathogenesis of Diabetic Nephropathy. Nat Rev Nephrol. 2011;7(6):327-340.
[9] ØSTERGAARD JA, COOPER ME, JANDELEIT-DAHM KAM. Targeting Oxidative Stress and Anti-Oxidant Defence in Diabetic Kidney Disease. J Nephrol. 2020;33(5):917-929.
[10] DE RECHTER S, DECUYPERE JP, IVANOVA E, et al. Autophagy in Renal Diseases. Pediatr Nephrol. 2016;31(5):737-752.
[11] KATO M, NATARAJAN R. Epigenetics and Epigenomics in Diabetic Kidney Disease and Metabolic Memory. Nat Rev Nephrol. 2019;15(6):327-345.
[12] DUCKWORTH W, ABRAIRA C, MORITZ T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129-139.
[13] NATIONAL KIDNEY FOUNDATION. Kdoqi Clinical Practice Guideline for Diabetes and Ckd: 2012 Update. Am J Kidney Dis. 2012;60(5):850-886.
[14] HALVORSEN YC, WILKISON WO, GIMBLE JM. Adipose-Derived Stromal Cells--Their Utility and Potential in Bone Formation. Int J Obes Relat Metab Disord. 2000;24 Suppl 4:S41-44.
[15] ZUK PA, ZHU M, MIZUNO H, et al. Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Eng. 2001;7(2):211-228.
[16] ROMANOV YA, SVINTSITSKAYA VA, SMIRNOV VN. Searching for Alternative Sources of Postnatal Human Mesenchymal Stem Cells: Candidate Msc-Like Cells from Umbilical Cord. Stem Cells. 2003;21(1):105-110.
[17] IN ‘T ANKER PS, SCHERJON SA, KLEIJBURG-VAN DER KEUR C, et al. Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta. Stem Cells. 2004;22(7):1338-1345.
[18] MELO FR, BRESSAN RB, FORNER S, et al. Transplantation of Human Skin-Derived Mesenchymal Stromal Cells Improves Locomotor Recovery after Spinal Cord Injury in Rats. Cell Mol Neurobiol. 2017;37(5):941-947.
[19] MARTINEZ SAEZ D, SASAKI RT, NEVES AD, et al. Stem Cells from Human Exfoliated Deciduous Teeth: A Growing Literature. Cells Tissues Organs. 2016;202(5-6):269-280.
[20] WANG Y, CHEN X, CAO W, et al. Plasticity of Mesenchymal Stem Cells in Immunomodulation: Pathological and Therapeutic Implications. Nat Immunol. 2014;15(11):1009-1016.
[21] GALIPEAU J, SENSÉBÉ L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018;22(6):824-833.
[22] SQUILLARO T, PELUSO G, GALDERISI U. Clinical Trials With Mesenchymal Stem Cells: An Update. Cell Transplant. 2016;25(5):829-848.
[23] TROUNSON A, MCDONALD C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell. 2015;17(1):11-22.
[24] NAJI A, ROUAS-FREISS N, DURRBACH A, CAROSELLA ED, et al. Concise Review: Combining Human Leukocyte Antigen G and Mesenchymal Stem Cells for Immunosuppressant Biotherapy. Stem Cells. 2013;31(11):2296-2303.
[25] WEI X, YANG X, HAN ZP, et al. Mesenchymal Stem Cells: A New Trend for Cell Therapy. Acta Pharmacol Sin. 2013;34(6):747-754.
[26] CHINNADURAI R, COPLAND IB, GARCIA MA, et al. Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing. Stem Cells. 2016;34(9):2429-2442.
[27] GALIPEAU J. The Mesenchymal Stromal Cells Dilemma--Does a Negative Phase Iii Trial of Random Donor Mesenchymal Stromal Cells in Steroid-Resistant Graft-Versus-Host Disease Represent a Death Knell or a Bump in the Road? Cytotherapy. 2013;15(1):2-8.
[28] GALIPEAU J, KRAMPERA M. The Challenge of Defining Mesenchymal Stromal Cell Potency Assays and Their Potential Use as Release Criteria. Cytotherapy. 2015;17(2):125-127.
[29] GALIPEAU J, KRAMPERA M, BARRETT J, et al. International Society for Cellular Therapy Perspective on Immune Functional Assays for Mesenchymal Stromal Cells as Potency Release Criterion for Advanced Phase Clinical Trials. Cytotherapy. 2016;18(2):151-159.
[30] PHINNEY DG, GALIPEAU J, KRAMPERA M, et al. Mscs: Science and Trials. Nat Med. 2013;19(7):812.
[31] PEIRED AJ, SISTI A, ROMAGNANI P. Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence. Stem Cells Int. 2016; 2016:4798639.
[32] ROVIRA J, DIEKMANN F, CAMPISTOL JM, et al. Therapeutic Application of Extracellular Vesicles in Acute and Chronic Renal Injury. Nefrologia. 2017; 37(2):126-137.
[33] MAKHLOUGH A, SHEKARCHIAN S, MOGHADASALI R, et al. Safety and Tolerability of Autologous Bone Marrow Mesenchymal Stromal Cells in Adpkd Patients. Stem Cell Res Ther. 2017;8(1):116.
[34] PACKHAM DK, FRASER IR, KERR PG, et al. Allogeneic Mesenchymal Precursor Cells (Mpc) in Diabetic Nephropathy: A Randomized, Placebo-Controlled, Dose Escalation Study. EBioMedicine. 2016;12:263-269.
[35] ABDEL AZIZ MT, WASSEF MA, AHMED HH, et al. The Role of Bone Marrow Derived-Mesenchymal Stem Cells in Attenuation of Kidney Function in Rats with Diabetic Nephropathy. Diabetol Metab Syndr. 2014;6(1):34.
[36] EZQUER F, GIRAUD-BILLOUD M, CARPIO D, et al. Proregenerative Microenvironment Triggered by Donor Mesenchymal Stem Cells Preserves Renal Function and Structure in Mice with Severe Diabetes Mellitus. Biomed Res Int. 2015;2015:164703.
[37] ZHANG L, LI K, LIU X, et al. Repeated Systemic Administration of Human Adipose-Derived Stem Cells Attenuates Overt Diabetic Nephropathy in Rats. Stem Cells Dev. 2013;22(23):3074-3086.
[38] LI D, WANG N, ZHANG L, et al. Mesenchymal Stem Cells Protect Podocytes from Apoptosis Induced by High Glucose Via Secretion of Epithelial Growth Factor. Stem Cell Res Ther. 2013;4(5):103.
[39] JIANG Y, ZHANG W, XU S, et al. Transplantation of Human Fetal Pancreatic Progenitor Cells Ameliorates Renal Injury in Streptozotocin-Induced Diabetic Nephropathy. J Transl Med. 2017;15(1):147.
[40] NI W, FANG Y, XIE L, et al. Adipose-Derived Mesenchymal Stem Cells Transplantation Alleviates Renal Injury in Streptozotocin-Induced Diabetic Nephropathy. J Histochem Cytochem. 2015;63(11):842-853.
[41] EBRAHIM N, AHMED IA, HUSSIEN NI, et al. Mesenchymal Stem Cell-Derived Exosomes Ameliorated Diabetic Nephropathy by Autophagy Induction through the Mtor Signaling Pathway. Cells. 2018;7(12):226.
[42] SUN J, LV J, ZHANG W, et al. Combination with Mir-124a Improves the Protective Action of Bmscs in Rescuing Injured Rat Podocytes from Abnormal Apoptosis and Autophagy. J Cell Biochem. 2018;119(9):7166-7176.
[43] ISLAM MN, GRIFFIN TP, SANDER E, et al. Human Mesenchymal Stromal Cells Broadly Modulate High Glucose-Induced Inflammatory Responses of Renal Proximal Tubular Cell Monolayers. Stem Cell Res Ther. 2019;10(1):329.
[44] AN X, LIAO G, CHEN Y, et al. Intervention for Early Diabetic Nephropathy by Mesenchymal Stem Cells in a Preclinical Nonhuman Primate Model. Stem Cell Res Ther. 2019;10(1):363.
[45] YU S, CHENG Y, ZHANG L, et al. Treatment with Adipose Tissue-Derived Mesenchymal Stem Cells Exerts Anti-Diabetic Effects, Improves Long-Term Complications, and Attenuates Inflammation in Type 2 Diabetic Rats. Stem Cell Res Ther. 2019;10(1):333.
[46] LI Y, LIU J, LIAO G, et al. Early Intervention with Mesenchymal Stem Cells Prevents Nephropathy in Diabetic Rats by Ameliorating the Inflammatory Microenvironment. Int J Mol Med. 2018;41(5):2629-2639.
[47] YUAN Y, LI L, ZHU L, et al. Mesenchymal Stem Cells Elicit Macrophages into M2 Phenotype Via Improving Transcription Factor Eb-Mediated Autophagy to Alleviate Diabetic Nephropathy. Stem Cells. 2020;38(5):639-652.
[48] ZHANG F, WANG C, WEN X, et al. Mesenchymal Stem Cells Alleviate Rat Diabetic Nephropathy by Suppressing Cd103(+) Dcs-Mediated Cd8(+) T Cell Responses. J Cell Mol Med. 2020;24(10):5817-5831.
[49] KONARI N, NAGAISHI K, KIKUCHI S, et al. Mitochondria Transfer from Mesenchymal Stem Cells Structurally and Functionally Repairs Renal Proximal Tubular Epithelial Cells in Diabetic Nephropathy in Vivo. Sci Rep. 2019;9(1):5184.
[50] LEE SE, JANG JE, KIM HS, et al. Mesenchymal Stem Cells Prevent the Progression of Diabetic Nephropathy by Improving Mitochondrial Function in Tubular Epithelial Cells. Exp Mol Med. 2019;51(7):77.
[51] HILLS CE, SQUIRES PE. The Role of Tgf-Beta and Epithelial-to Mesenchymal Transition in Diabetic Nephropathy. Cytokine Growth Factor Rev. 2011;22(3): 131-139.
[52] ZIYADEH FN. Mediators of Diabetic Renal Disease: The Case for Tgf-Beta as the Major Mediator. J Am Soc Nephrol. 2004;15 Suppl 1:S55-57.
[53] TONOLO G, CHERCHI S. Tubulointerstitial Disease in Diabetic Nephropathy. Int J Nephrol Renovasc Dis. 2014;7:107-115.
[54] RAO N, WANG X, XIE J, et al. Stem Cells from Human Exfoliated Deciduous Teeth Ameliorate Diabetic Nephropathy in Vivo and in Vitro by Inhibiting Advanced Glycation End Product-Activated Epithelial-Mesenchymal Transition. Stem Cells Int. 2019;2019:2751475.
[55] NAGAISHI K, MIZUE Y, CHIKENJI T, et al. Mesenchymal Stem Cell Therapy Ameliorates Diabetic Nephropathy Via the Paracrine Effect of Renal Trophic Factors Including Exosomes. Sci Rep. 2016;6:34842.
[56] LV SS, LIU G, WANG JP, et al. Mesenchymal Stem Cells Transplantation Ameliorates Glomerular Injury in Streptozotocin-Induced Diabetic Nephropathy in Rats Via Inhibiting Macrophage Infiltration. Int Immunopharmacol. 2013;17(2):275-282.
[57] MOTAZED R, COLVILLE-NASH P, KWAN JT, et al. Bmp-7 and Proximal Tubule Epithelial Cells: Activation of Multiple Signaling Pathways Reveals a Novel Anti-Fibrotic Mechanism. Pharm Res. 2008;25(10):2440-2446.
[58] LUO DD, PHILLIPS A, FRASER D. Bone Morphogenetic Protein-7 Inhibits Proximal Tubular Epithelial Cell Smad3 Signaling Via Increased Snon Expression. Am J Pathol. 2010;176(3):1139-1147.
[59] LV S, LIU G, SUN A, et al. Mesenchymal Stem Cells Ameliorate Diabetic Glomerular Fibrosis in Vivo and in Vitro by Inhibiting Tgf-Beta Signalling Via Secretion of Bone Morphogenetic Protein 7. Diab Vasc Dis Res. 2014; 11(4):251-261.
[60] BAI Y, WANG J, HE Z, et al. Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease Via Lipoxin A4 by Targeting Transforming Growth Factor Beta (Tgf-Beta)/Smad Pathway and Pro-Inflammatory Cytokines. Med Sci Monit. 2019;25:3069-3076.
[61] ZHONG L, LIAO G, WANG X, et al. Mesenchymal Stem Cells-Microvesicle-Mir-451a Ameliorate Early Diabetic Kidney Injury by Negative Regulation of P15 and P19. Exp Biol Med (Maywood). 2018;243(15-16):1233-1242.
[62] GRANGE C, TRITTA S, TAPPARO M, et al. Stem Cell-Derived Extracellular Vesicles Inhibit and Revert Fibrosis Progression in a Mouse Model of Diabetic Nephropathy. Sci Rep. 2019;9(1):4468. |